(NASDAQ: DWTX) Dogwood Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.
Dogwood Therapeutics's earnings in 2026 is -$36,041,288.On average, 4 Wall Street analysts forecast DWTX's earnings for 2026 to be -$30,338,354, with the lowest DWTX earnings forecast at -$31,647,067, and the highest DWTX earnings forecast at -$28,553,745. On average, 4 Wall Street analysts forecast DWTX's earnings for 2027 to be -$24,964,131, with the lowest DWTX earnings forecast at -$25,983,908, and the highest DWTX earnings forecast at -$23,556,839.
In 2028, DWTX is forecast to generate -$26,524,389 in earnings, with the lowest earnings forecast at -$30,980,813 and the highest earnings forecast at -$21,415,308.